DCB vs. DES in Young STEMI Patients: The DCB-STEMI Trial

National Institute of Cardiovascular Diseases, Pakistan

Status and phase: Enrolling; Phase 3

Conditions: STEMI (ST Elevation MI)

Treatments: Device: Drug coated balloon (Prevail; Medtronic Inc.); Device: Drug eluting stent

Study type: Interventional

Funder types: Other

Identifiers

NCT07229248

NICVD IRB-32/2025

Details and patient eligibility

About

Background: ST Elevation Myocardial Infarction (STEMI) in young adults (<50 yrs) carries high Percutaneous coronary intervention (PCI) risks. While drug-eluting stents (DES) reduce restenosis versus angioplasty, they increase risks of in-stent restenosis, thrombosis, prolonged dual antiplatelet therapy (DAPT), and endothelial dysfunction. Drug-coated balloons (DCB) provide a "leave nothing behind" strategy, potentially mitigating these issues. Evidence, including a JACC CVI report, suggests DCB outcomes comparable to DES in STEMI. South Asia faces a heavy burden. The national Institute of Cardiovascular diseases (NICVD), Karachi performed 17,761 primary PCIs in 2022, with 45% in patients <50 yrs.

Study Design: This single-center Randomized Controlled Trial (RCT) compares paclitaxel-coated DCB (3.0 µg/mm², 30s inflation) vs. Drug eluting stents (DES) in young STEMI patients (<50 yrs) undergoing primary PCI. The primary endpoint is 1-year vessel oriented cardiac events (VOCE)= Cardiovascular /all-cause death, target vessel MI, or Target lesion revascularization (TLR). Secondary endpoints include vessel-oriented CV events, bleeding, TIMI III flow, residual stenosis, abrupt closure, and bailout stenting. An intravascular ultrasound (IVUS) substudy (100 DCB pts) will evaluate remodeling and late lumen loss (LLL) at 6 months.

Methods: 496 patients (248/arm) will be randomized 1:1, powered for non-inferiority (margin 4.5%) assuming VOCE 8.5% (DES) vs. 6.25% (DCB), 80% power, and 5% dropout. Inclusion: age 18-50, STEMI. Exclusion: End stage renal disease (ESRD), severe multivessel disease, complex lesions, or high thrombus burden. All will receive ticagrelor 90 mg BID for 1 month. A pilot of 50 pts will first assess safety (abrupt closure, lesion prep).

Analysis: Intention-to-treat (ITT) will be primary; modified ITT for secondary endpoints. Statistics include chi-square/Fisher for categorical, t-test/Wilcoxon for continuous, and Kaplan-Meier/Cox for survival. Oversight by data safety monitoring board (DSMB) and Events adjudication Committee (EAC).

Significance: This trial leverages NICVD's high PCI volume to test DCB as an alternative to DES in young STEMI patients. By avoiding permanent implants, DCB may reduce long-term complications and DAPT needs. The IVUS substudy and pilot phase strengthen rigor. If non-inferiority is proven, DCB could reshape STEMI management in South Asia and similar high-burden regions.

Full description

INTRODUCTION Patients with acute myocardial infarction (AMI) are among the highest-risk patients undergoing PCI and are mostly treated with drug-eluting stents (DES). Stenting reduces elastic recoil, restenosis, and flow-limiting dissections associated with balloon angioplasty. However, it increases the risk of in-stent restenosis (ISR), bleeding from prolonged dual antiplatelet therapy (DAPT), early and late stent thrombosis, and endothelial and vasomotor dysfunction.

In young patients (<50 years), lifetime management after stenting carries unique economic and social consequences. Stent implantation means a lifelong risk of ISR, stent thrombosis, and strict adherence to DAPT-a major compliance and financial issue in this age group.

These limitations have led to the development of drug-coated balloons (DCB), which deliver antiproliferative drugs into the vessel wall without leaving a permanent implant. This "leave nothing behind" strategy is particularly attractive in young patients and those with high bleeding risk. DCBs have shown promise in ISR, small vessel disease, and STEMI. Paclitaxel-coated balloons are most commonly used, delivering 2.0-3.5 µg/mm² of paclitaxel with cytotoxicity lasting at least 14 days. With a 30-second balloon inflation, about 16% of the drug is transferred to the vessel wall, ensuring homogenous delivery while avoiding permanent implants, stent thrombosis, ISR, and prolonged DAPT.

Several studies and meta-analyses have demonstrated comparable outcomes between DCBs and DES in AMI, including STEMI. In a large multicenter analysis of STEMI patients, DCBs were associated with similar mortality and target lesion revascularization compared to DES. Other feasibility studies confirmed no excess risk of abrupt closure, thrombosis, or target vessel failure when DCBs were used in primary PCI.

Cardiovascular disease, especially AMI, remains the leading global cause of death. South Asia bears a particularly high burden, with Pakistan at the top for premature MI. The National Institute of Cardiovascular Diseases (NICVD), Karachi, has become the world's largest primary PCI center, performing 17,761 primary PCIs in 2022. Notably, 45% were in young patients (<50 years) and 12% in very young (<40 years). This provides a unique opportunity to study DCB vs DES in a high-volume RCT focused on young STEMI patients.

________________________________________ STUDY DESIGN This is a randomized controlled trial comparing DCB vs DES in young (<50 years) STEMI patients undergoing primary PCI.

Hypothesis: DCB is non-inferior to DES in reducing Vessel Oriented Composite Endpoint (VOCE) at one year.

Primary Objective: Compare 1-year VOCE between DCB and DES in young STEMI patients.

Secondary Objectives: Compare vessel-oriented CV events, target vessel failure, vessel-related MI, stent thrombosis, bleeding, TIMI III flow, residual stenosis, abrupt closure, and bailout stenting.

________________________________________ METHODS

• Design: Single-center RCT at NICVD Karachi.
• Duration: 12 months.
• Randomization: Block randomization (1:1) using sealed envelopes.
• Sample Size: 496 patients (248 per arm). Based on non-inferiority design, assuming VOCE 8.5% with DES and 6.25% with DCB, non-inferiority margin 4.5%, 80% power, 5% dropout.

Inclusion Criteria:

• Age 18-50 years
• STEMI as first coronary artery disease (CAD) presentation
• Primary PCI within 8 hours of ischemia
• Low SYNTAX score
• Killip class I-II

Exclusion Criteria:

• ESRD
• Severe 3-vessel disease or high SYNTAX score
• Complex lesions >B or large thrombus despite preparation
• Refusal of consent
• Killip III/IV
• Major bleeding history

INTERVENTIONS

• DCB Arm: Paclitaxel-coated balloon (3.0 µg/mm²), inflated for 30 seconds after adequate lesion preparation. Successful result defined as TIMI III flow, ≤30% residual stenosis, and absence of major dissection. Bailout stenting permitted if needed, but patient analyzed in DCB arm (intention-to-treat).
• DES Arm: Standard second-generation drug eluting stent with routine lesion preparation.

IVUS Substudy:

100 patients in the DCB arm will undergo IVUS at baseline, post-procedure, and 6 months to assess vessel remodeling and late lumen loss.

DAPT Protocol:

Ticagrelor 90 mg BID for 1 month post-PCI, followed by DAPT up to 1 year.

________________________________________ DATA COLLECTION & FOLLOW-UP

• Baseline demographics, risk factors, and angiographic data recorded.
• Clinical follow-up at 14 days, 30 days, 3 months, 6 months, and 12 months via visit/phone.
• Events tracked: death, MI, stent thrombosis, bleeding, stroke, repeat PCI, CABG, arrhythmias, and adverse drug reactions.
• Data captured on CRFs and stored securely.

ENDPOINTS

Primary Endpoint:

• 1-year VOCE (all-cause mortality, target vessel MI, TLR).

Secondary Endpoints:

• TIMI III flow rates
• Residual stenosis (>30% in DCB, >20% in DES)
• Bailout stenting
• Vessel-oriented events
• Bleeding

QUALITY CONTROL & ETHICS

• Ethics approval obtained from NICVD.
• Written informed consent (English/Urdu).
• Independent DSMB to monitor safety and review pilot data weekly.
• Event Adjudication Committee to validate endpoints.
• Data stored per GCP for 10 years.
• Medtronic to provide financial support but with no role in design, conduct, or analysis.

PILOT PHASE An initial pilot of 50 patients will assess safety of the DCB-only strategy in STEMI. Focus will be on lesion preparation, abrupt closure, and bailout stenting. If safe, full enrollment will proceed.

________________________________________ STATISTICAL ANALYSIS

• Population: Intention-to-treat for efficacy; modified ITT for safety.
• Categorical Variables: Chi-square or Fisher's exact.
• Continuous Variables: T-test or Wilcoxon rank-sum.
• Time-to-Event: Kaplan-Meier with log-rank test; Cox regression for hazard ratios and subgroup analysis.
• Significance: p<0.05.
• Subgroups: Age (<40 vs ≥40), sex, smoking, diabetes, renal function, weight.

SIGNIFICANCE This trial addresses a critical gap in managing young STEMI patients in South Asia, a population with extremely high disease burden and unique socioeconomic challenges. If non-inferiority of DCB is confirmed, it could reshape PCI practice by reducing long-term stent-related complications, improving compliance, and lowering financial strain in younger patients.

Enrollment: 496 estimated patients

Sex: All

Ages: 18 to 49 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Either gender
• Patient of age between 18 to 50 years
• Patients with STEMI ( as first presentation of CAD) undergoing Primary PCI
• Total ischemic Time less than 8 hrs.
• Low syntax score
• Stable (Killip I-II)

Exclusion criteria

• Patients with ESRD
• Severe 3 VD; Intermediate of High syntax score
• Lesion type>B

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

496 participants in 2 patient groups

DCB arm (Prevail Drug Coated Balloon)

Experimental group

Description:

Patients assigned to drug coated balloon

Treatment:

Device: Drug coated balloon (Prevail; Medtronic Inc.)

DES arm (Limus drug eluting stent)

Active Comparator group

Description:

Patients receiving standard of care Drug eluting stent

Treatment:

Device: Drug eluting stent